Summary
This report by Kerrisdale Capital Management presents a critical review of Altimmune Inc, a pharmaceutical company focused on developing the GLP-1 agonist pemvidutide for weight loss and NASH treatment. Kerrisdale argues that pemvidutide is an inferior drug compared to competitors and questions Altimmune's management and commercial prospects.
Who is Altimmune Inc
Altimmune Inc is a pharmaceutical company developing treatments primarily in the metabolic disease space, notably focusing on the GLP-1 agonist called pemvidutide. The company arose from a reverse merger in 2017 and originally focused on vaccine developments, including an intranasal COVID-19 vaccine. Currently, its lead drug pemvidutide targets obesity and NASH (non-alcoholic steatohepatitis) but has yet to complete phase-3 clinical trials. The firm has a history of capital raising with limited commercial success.
Key Points from Report
Pemvidutide's Inferior Efficacy
- Pemvidutide showed a reported 15.6% weight loss at 48 weeks on the highest dose (2.4mg), comparable to semaglutide but inferior to tirzepatide (17-18%).
- Unlike competitors, pemvidutide does not control blood sugar, a crucial therapeutic benefit for diabetic patients.
- Statistical analysis suggests the 15.6% efficacy may be a fluke; actual real-world phase-3 results are likely closer to 10% weight loss.
Poor Tolerability and High Discontinuation Rates
- Pemvidutide’s phase-2 trial had up to 42% discontinuation rate at the 2.4mg dose, compared to 15-17% for semaglutide and tirzepatide.
- These high dropout rates occurred despite offering a highly sought-after weight-loss medication for free during a period of high demand and limited supply of alternatives.
- Management's claims that dose titration and dose reduction will improve tolerability lack support; even lower doses show high dropout.
Competitive and Management Challenges
- Altimmune's pemvidutide is at a competitive disadvantage given the crowded GLP-1 drug pipeline with superior candidates from large pharmaceutical companies.
- Management has a history of raising capital for failed pharmaceutical ventures and exploiting market conditions (e.g., COVID-19 vaccine hype) without delivering successful drugs.
- Company faces financial constraints with limited cash runway and unlikely to attract high-quality partners due to weak clinical data.
Activ8 Finance Analysis
The Kerrisdale report raises substantial concerns about Altimmune’s flagship product pemvidutide, highlighting its efficacy and tolerability shortcomings relative to established and emerging GLP-1 agonists. From an investment viewpoint, these factors combined with management’s questionable track record and the highly competitive market environment introduce significant risks. Moreover, the financial situation suggests constrained resources for the challenging phase-3 development ahead. While not offering direct investment advice, stakeholders may consider these headwinds as potential indicators of operational and market risks facing Altimmune moving forward.